1 High glycaemic variability in individuals with type 1 diabetes is associated

2 with a reduced proportion of CD8⁺ TNF⁺ cells in response to influenza A virus

3 Marcus Tong Zhen Wei^{1*}, Katina D. Hulme^{1,2*}, Soi Cheng Law³, Ellesandra Noye¹, Emily S. Dorey³, Keng Yih

4 Chew¹, , Louise C. Rowntree⁵, Carolien E. van de Sandt^{5,6}, Katherine Kedzierska⁵, Marco Goeijenbier^{8,9},

5 Katharina Ronacher^{3,7}, Fawaz Alzaid^{10,11}, Jean-Baptiste Julla^{10,12}, Jean-Pierre Riveline^{10,12}, Katie Lineburg¹³,

6 Corey Smith^{13,14}, Emma J. Grant^{15,16}, Stephanie Gras^{15,16}, Linda A. Gallo¹⁷, Helen L. Barett^{3, 18,19}, Kirsty R.

7 Short^{1,7,14+}

8 <u>Affiliations:</u>

- 9 1. School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Australia
- 2. Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam,
 Netherlands
- 12 3. Mater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia
- 13 5. Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for
- 14 Infection and Immunity, Melbourne, VIC, Australia
- 15 6. Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University
- 16 of Amsterdam, Amsterdam, The Netherlands
- 17 7. Australian Infectious Diseases Research Centre, The University of Queensland, St Lucia, Australia
- 18 8. Department of intensive care, Erasmus MC, Rotterdam, The Netherlands
- 19 9. Department of intensive care, Spaarne Gasthuis, Haarlem/Hoofddorp, The Netherlands
- 20 10. Université Paris Cité, CNRS, INSERM, Institut Necker Enfants Malades-INEM, F-75015 Paris, France
- 21 11. Dasman Diabetes Institute, Kuwait, Kuwait
- 22 12. Department of Diabetes, Clinical Investigation Centre (CIC-9504), Lariboisière Hospital, Assistance Publique
- 23 Hôpitaux de Paris, Paris, France
- 24 13. QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
- 25 14. Queensland Immunology Research Centre, St Lucia, Australia
- 26 15. Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, Bundoora, Australia
- 16. Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Clayton,
 Australia
- 29 17. School of Health and Behavioural Sciences, University of the Sunshine Coast, Petrie, Australia
- 30 18. University of New South Wales Medicine, Kensington, Australia
- 31 19.. Obstetric Medicine, Royal Hospital for Women, Randwick, Australia
- 32
- 33 * These authors contributed equally to this study
- 34 + email: <u>k.short@uq.edu.au</u>

35		
36		
37		
38		
39		
40		
41		
42		
43		
44	ABSTACT:	

45 *Objective:* Diabetes mellitus significantly increases the risk of severe respiratory virus disease like 46 influenza and COVID-19. Early evidence suggests that this susceptibility to respiratory viral disease is 47 driven by glycaemic variability, rather than average blood glucose levels. In healthy individuals, 48 blood glucose levels remain relatively stable throughout the day. However, in individuals living with 49 diabetes, blood glucose spikes are more frequent and higher in magnitude. Continuous glucose 50 monitoring (CGM) provides a unique opportunity to detect these hyper and hypoglycaemic events, 51 even in the presence of an in range HbA1c.

Research design and methods: Here, we use blood samples and CGM data obtained from people living with Type 1 diabetes (T1D) to determine the effects of glycaemic variability on the T-cell response to influenza virus. Low glycaemic variability was defined as a coefficient of variation (CV) <33% (n = 13) whilst high glycaemic variability was defined as a CV \geq 33% (n = 19).

Results: We show that high glycaemic variability in participants living with T1D is associated with a reduced proportion of CD8⁺CD107 α ⁻IFN γ ⁻MIP1 β ⁻TNF⁺ T-cells in response to stimulation with influenza virus and an influenza peptide pool. High glycaemic variability in this patient population is primarily driven by hypoglycaemic events and was also associated with an increase in the proportion of naïve CD8⁺ T cells and a decrease in terminally differentiated CD8⁺ T cells (T_{EMRA}).

61 Conclusions: Together, this study provides the first evidence that glycaemic variability affects the T-

62 cell response to respiratory viruses. These data suggest that monitoring glycaemic variability may

have important implications in understanding the antiviral immune response in people with diabetes.

- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74 75
- 76
- 77
- 78
- 79
- 19
- 80 INTRODUCTION:

81 Diabetes mellitus (both type 1 [T1D] and type 2 [T2D]) significantly increases the risk of severe respiratory virus infections¹⁻⁴. The mechanisms by which this occurs remain poorly defined. 82 Hyperglycaemia (high blood glucose levels) is typical of both T1D and T2D and its persistence is 83 84 indicated by elevated glycated haemoglobin (HbA1C) levels. Hyperglycaemia is associated with 85 increased susceptibility to severe disease, including respiratory tract infections. A meta-analysis 86 showed that chronic hyperglycaemia (HbAa1c levels ≥7.0%) is associated with at least a 2.5 fold 87 increased risk of pulmonary tuberculosis relative to patients with lower (<7.0%) HbA1c levels⁵. Hyperglycaemia (relative to in range blood glucose levels) also significantly increased the risk of 88 89 mortality, ICU admission and intubation for COVID-19 in patients with T2D⁶. Similarly, in vitro high glucose levels increase pulmonary epithelial-endothelial damage from influenza virus infection⁷. An 90 91 elevated HbA1C in patients with diabetes is also associated with impaired TNF production by $CD8^+T$ 92 cells⁸.

93 In contrast to consistently high average blood glucose levels there is now a growing body of evidence 94 that glycaemic variability may also play a significant role in susceptibility to severe respiratory virus infections^{4,9-13}. Typically, in healthy individuals blood glucose levels remain relatively stable 95 throughout the day except for small and short-lived post-prandial peaks. However, in individuals 96 97 living with diabetes these postprandial glucose spikes are more frequent and higher in magnitude. 98 This glycaemic variability is not indicated in measurements of a patient's HbA1c, which largely 99 reflects a 3-month average of blood glucose levels in terms of the percentage of glycated 100 haemoglobin. Instead, blood glucose variability can be detected using continuous glucose monitors 101 (CGM). Indeed, CGM data has shown that both T1D patients and T2D patients experience significant 102 fluctuations in blood glucose levels over time^{14,15}. In contrast, healthy individuals with CGM data display minimal, if any, out of range fluctuations¹⁶. Several studies have shown that glycaemic 103 variability increases the severity of COVID-19^{4,11-13} and there is evidence that a similar phenomenon 104 occurs with influenza virus⁹. However, such studies typically depend on successive measurements of 105 106 an individual's blood glucose levels (rather than CGM data) and the mechanisms underlying this 107 association remains to be determined.

Here, we hypothesise that high glycaemic variability (as determined by CGM data) reduces the anti viral immune response to influenza virus.

121 MATERIALS AND METHODS:

122 Influenza virus culture

123 Virus stocks of HKx31 (H3N2) were prepared in embryonated chicken eggs and titres of infectious 124 virus were determined by plaque assays on MDCK cells as previously described¹⁷. The use of 125 embryonated chicken eggs was approved by the University of Queensland Animal Ethics Committee 126 (AE000089).

127 **Participant recruitment**

128 A cohort of 32 people with clinically diagnosed T1D who were routinely using continuous, or flash 129 glucose monitoring (CGM) devices were recruited in Brisbane, Australia between 8/6/21 and 130 11/11/21. These individuals were a subset of a previously described cohort of 72 patients with diabetes mellitus (T1D and T2D)¹⁸. Inclusion criteria were 18-60 years of age, not pregnant at the 131 132 time of study, non-smokers of nicotine cigarettes, minimum diabetes mellitus duration of two years 133 and no known immune disease requiring immunosuppressants. Blood, clinical data, and two weeks 134 of prior CGM data from these participants were collected at the point of recruitment. To further 135 establish the quality of CGM data, only samples with CGM time worn above 70% were included in the analysis. This study was approved by Mater Research Ethics Committee (HREC/MML/55151 V2) 136 137 and the University of Queensland Ethics Committee (2019/HE002522). All methods were performed 138 in accordance with institutional guidelines and regulations. Written consent was obtained from all 139 study participants.

140 Glycaemic variability

141 Glycaemic variability was determined based on an individual's coefficient of variation (CV; glucose

- 142 SD expressed as a percentage of the mean glucose) reading from their CGM with the threshold set at
- 143 33.0% as described previously¹⁹.

144 Human PBMC isolation

10mL of whole peripheral blood was collected in BD Vacutainer[®] EDTA tubes (BD Biosciences).
Peripheral blood mononuclear cells (PBMC) were isolated with Lymphoprep (STEMCELL, Canada)
according to manufacturer's instructions. Isolated PBMC were subsequently frozen down in Fetal
Calf Serum (FCS) (Gibco) containing 10% DMSO (Sigma-Aldrich) at -80 ^[D]C until analysis.

149 Human T-cell phenotype characterisation

To study the effects of glycaemic variability on CD8⁺T-cell phenotypic markers, PBMCs isolated from participants were stained as previously described²⁰. Briefly, T-cells were washed and stained for lymphocyte (anti-CD3; anti-CD4 anti-CD8) and differentiation markers (anti-CD27, anti-CD45RA and anti-CD95) (Key Resource Table). T-cells were subsequently washed and fixed. All samples were analysed on LSRFortessa (BD Biosciences) and analysed using FlowJo v10.8 (BD Biosciences). Gating was performed as previously described⁸.

156 T-cell stimulation and intracellular cytokine staining (ICS) on human PBMC

To investigate the effect of glycaemic variability on the cytokine response of T-cells *ex vivo*, PBMCs
 from each donor were stimulated with either i) HKx31 (multiplicity of infection 10), ii) 25ng/mL
 phorbol myristate acetate and 1µg/mL lonomycin (PMA/I Sigma Aldrich) iii) CD3/CD28 magnetic
 beads (Thermo Fisher; Dynabeads) or iii) influenza virus peptide pool (4µg/mL; AnaSpec)
 (Supplementary Table 1) in RPMI1640 (Gibco) with 10% FCS (Gibco) as described previously⁸.

Stimulations were performed for 18 hours (influenza virus, influenza virus peptide pool) in the presence of anti-CD107a (0.4µg/mL; BioLegend; H4A3), BD GolgiStop and BD GolgiPlug (BD Biosciences). T-cells were subsequently washed and stained for anti-CD3, CD4 and CD8 (Key Resource Table). T-cells were then washed, fixed, and permeabilised using the BD Cytofix/Cytoperm Fixation/Permeabilization kit (BD Biosciences) and stained with anti-MIP1 β , anti-IFNy and anti-TNF (Key Resource Table). Cells were analysed on the LSRFortessa (BD Biosciences) and analysed using FlowJo v10.8 (BD Biosciences). To assess the functionality of these T-cells, the number of MIP-1 β +, IFNγ+, TNF+ and CD107a+ cells were assessed according to our previously described gating strategy⁸.

170 Statistical analysis

171 Statistical analyses were performed with GraphPad Prism software (version 9.3.1) (Dotmatics, CA, 172 USA). After determining the normality of distribution with Shapiro-Wilk normality test, outliers 173 within data sets were removed according to the ROUT (1%) test. Continuous data were tested for 174 statistical significance with a Mann-Whitney test or t-test as appropriate. Categorical data were 175 tested for statistical significance with a chi-square test. Multiple linear regression was performed 176 with R software version 4.1.1 (The R Project).

197

198 **RESULTS:**

199 To investigate the effect of glycaemic variability on anti-viral T-cell populations, 32 participants with 200 T1D were recruited. These participants all had at least two weeks of CGM data available for analysis. 201 Using a CV threshold of 33%, participants were classified as having either low (n = 13) or high (n = 19) 202 glycaemic variability. Participants with low and high glycaemic variability were of equivalent age, sex 203 distribution, type of insulin treatment (injection/pump), body mass index (BMI) and had a similar 204 duration of diabetes (approximately 15 years; Table 1) and recent history of influenza virus infection. 205 Importantly, participants with low and high glycaemic variability had equivalent HbA1c levels and 206 blood glucose levels at the time of sample collection (Table 1). The high glycaemic variability group 207 had a lower rate of influenza virus vaccination within the last 6 months (Table 1). Patients reported 208 taking several other medications asides from those associated with diabetes management, the most 209 common of which was some form of contraception (Supplementary Table 2).

210

211 Table 1: Participant characteristics using a threshold of 33% CV¹

	Low glycaemic variability (n = 13)	High glycaemic variability (n = 19)	
	Mean (SD)	Mean (SD)	P value ²
Age (years)	29.88 (±11.69)	26.49 (±6.67)	0.6172
Sex (male;female)	4;9	6;13	0.5993
BMI (kg/m²)	26.33 (±4.79)	26.45 (±4.94)	>0.9999
HbA1c (%)	7.92 (±1.75)	7.75 (±1.42)	0.5505
Diabetes duration (years)	14.54 (±9.12)	15.15 (±5.24)	0.6151
Average blood glucose (mmol/L) ³	11.83 (±3.54)	9.83 (±2.65)	0.0823
CV (%)	27.01 (±4.32)	39.15 (±3.25)	<0.0001 (*)
Type of insulin treatment (injection;pump) ⁴	4;9	9;10	0.3477
Time in range	38.38 (±28)	56.95 (20.85)	0.04(*)
Influenza virus vaccination (Y;N)	10;3	5;14	0.0048 (*)
Recent respiratory virus infection (Y;N)	0;13	0;19	-

212 1. Abbreviations: BMI body-mass index, HbA1c glycated haemoglobin Type A1C, CGM continuous glucose 213 monitor, CV coefficient of variation. Participants were grouped based on their CV% from CGM data, threshold 214 set at 33%. 2. P-value was determined wither either Mann-Whitney test (age, BMI, diabetes duration, average 215 glucose), a t-test (time in range) or chi-square test at a 0.05 significance level (sex, type of insulin treatment, 216 influenza virus vaccination history, SARS-CoV-2 vaccination). 3. Average blood glucose levels were recorded as 217 an average of all glucose readings across time worn. 4. Insulin regime (basal vs. bolus, long lasting vs fast 218 acting insulin) was not recorded. 5. 12/13 individuals received two vaccine doses; 1 individual only received

one 6. All individuals received two vaccine doses with the exception of one individual for whom data was notavailable.

To demonstrate the glycaemic profile in high and low glycaemic variability, representative CGM data from each group is shown in Fig. 1A. To evaluate the differences in glycaemic profile between low glycaemic variability and high glycaemic variability with a CV threshold at 33%, the time glucose levels were above and below the healthy range (3.9mmol/L – 10.0mmol/L) were assessed (Fig. 1B). Participants with high glycaemic variability had significantly lesser time spent with hyperglycaemic levels, but significantly higher time spent with hypoglycaemic levels (Figure 1B).





Figure 1. Higher time recorded with hypoglycaemic levels were observed in participants with high glycaemic variability (GV). (A). Representative CGM data for individuals with low glycaemic variability and high glycaemic variability (B). The difference in time glucose levels spent above and below the glycaemic healthy range (3.9mmol/L to 10.0mmol/L) were analysed between both groups. Statistical significance was assessed as described in the Materials and Methods. P< 0.05 *; P<0.001 ***

To characterise the T-cell populations of both participant groups the percentage of circulating CD4⁺ and CD8⁺ T-cells were assessed. There was no significant difference in the percentage of CD4⁺, CD8⁺, the ratio of CD4:CD8 cells or CD4⁻CD8⁻ T-cells between those with low glycaemic variability and high glycaemic variability (Fig. 2A). To better define the subsets of CD4⁺ and CD8⁺ T-cells the percentage of circulating naïve T-cells (T_{naive} ; CD27⁺CD45RA⁺CD95⁻), stem cell memory T-cells (T_{SCM} ; CD27⁺CD45RA⁺CD95⁺), central memory T-cells (T_{CM} ; CD27⁺CD45RA⁻), effector memory T-cells (T_{EMR} ; CD27⁻CD45RA⁻) and effector memory re-expressing CD45RA T-cells (T_{EMRA} ; CD27⁻CD45RA⁺) of the

total CD4⁺ and CD8⁺ T-cell populations were established (Fig. 2B). No significant differences were seen in the CD4⁺ T-cell subsets between the two participant groups (Fig. 2B). In contrast, patients with high glycaemic variability had a significantly higher percentage of T_{naive} CD8⁺ T-cells but a significantly lower percentage of T_{EMRA} CD8⁺ T-cells compared to patients with low glycaemic variability (Fig. 2B).

246 Next, the cytokine response of T-cells to ex vivo stimulation with infectious influenza virus was 247 assessed (Fig. 2C). In terms of CD4+ T-cells, a lower proportion of CD107a⁺IFNy MIB1b⁺TNF⁺, 248 $CD107a^{+}$ IFNy MIB1bTNF⁺ and CD107a IFNy MIB1bTNF⁺ cells were observed in individuals with high 249 GV. In terms of CD8+ T-cells, a lower proportion of CD107a⁺IFNy MIB1b⁺TNF⁺, CD107a⁻IFNy⁺MIB1b⁻ 250 TNF and CD107a IFNy MIB1b TNF⁺ cells were observed in individuals with high GV (Fig. 2C). We then sought to validate these observations in CD8+ T-cells stimulated with an influenza virus peptide pool 251 252 (Fig. 2D). Consistent with the observations using infectious virus, low glycaemic variability samples 253 treated with influenza virus peptide pool had a significantly higher proportion of CD8⁺CD107a⁺IFNy⁻ 254 MIP1 β ⁺TNF⁺ relative to healthy controls and high glycaemic variability samples (Fig. 2D). Also 255 consistent with our infectious influenza virus stimulations, high glycaemic variability samples 256 stimulated with influenza peptides had a significantly lower proportion of CD8⁺C107a⁻IFNy MIP1b⁻ 257 TNF^{\dagger} T-cells compared to low glycaemic variability samples (Fig. 2D). When the proportion of any 258 CD8⁺TNF⁺ cell after IAV or IAV peptide pool stimulation was examined significantly higher 259 proportions were still observed in low glycaemic variability samples (Supplementary Fig. 1). Given 260 that a decreased proportion of CD8⁺C107a IFNy MIP1b TNF⁺ cells in high glycaemic variability 261 samples were consistently observed between influenza virus and influenza peptide pool stimulations 262 and showed the largest difference relative to low glycaemic variability samples, we elected to focus 263 on this population.

264

265 We next sought to determine if individuals with high glycaemic variability continued to display a 266 decreased proportion of CD8⁺CD107a⁻IFNy⁻MIP1B⁻TNF⁺ cells in response to non-specific stimuli like 267 PMA/I and Dynabeads (CD3/CD28) (Fig. 2E & F). Interestingly, unlike influenza virus stimulations, 268 there were several incidences of CD4+ and CD8+ T-cell populations being higher in individuals with 269 high glycaemic variability following this non-specific stimulation. Furthermore, unlike influenza virus 270 stimulations, there was no significant difference in the proportion of CD8⁺CD107a IFNy MIP1 β TNF⁺ 271 between healthy donors, those with high glycaemic variability and those with low glycaemic 272 variability in response to either PMA/I (Fig. 2E) or Dynabeads (Fig. 2F). Taken together, these data 273 suggest that the observed phenotype may be specific to influenza virus or perhaps more broadly 274 viral peptides.

275 One limitation of these analyses is that some of the observed changes to influenza virus stimulation 276 may be the result of a differential influenza virus vaccination history between those with low and 277 high glycaemic variability (Table 1), although as an inactivated subunit vaccine vaccination does not 278 typically induce strong cellular immunity. Nevertheless, we investigated the ex vivo CD8+ T-cell 279 response follow influenza virus stimulation exclusively in influenza vaccinated individuals. Consistent 280 with our original observations influenza vaccinated individuals with low glycaemic variability had a 281 higher proportion of CD8⁺CD107a⁺IFNy MIP1 β ⁺TNF⁺ cells (Supplementary Fig. 2). Furthermore, those 282 with low glycaemic variability had a trend towards an increased percentage of CD8⁺ CD107a IFNy 283 MIP-1 β TNF⁺ T-cells (p = 0.05; Supplementary Fig. 2). This held true when the proportion of any 284 CD8⁺TNF⁺ cell after IAV stimulation was examined (Supplementary Fig. 2). To further complement 285 these results, we performed a multiple linear regression model looking at the relationship between 286 glycaemic variability, influenza vaccination status and the percentage of CD8+CD107a IFNy MIP-1 β

- 287 TNF⁺ T-cells. Importantly glycaemic variability (high vs low) had a significant relationship with the
- 288 percentage of CD8+ CD107a⁻IFNy⁻MIP-1 β ⁻TNF⁺ (p = 0.04) T-cells whilst influenza vaccination did not
- 289 (p = 0.350).

290

291



Fig. 2. Participants with higher glycaemic variability (GV) exhibit an altered T-cell profile and proportion of TNF α + cells in response to influenza virus stimulation. PBMC from participants were stained for CD4 and CD8. CD4⁺, CD4⁻CD8⁻ and CD8⁺ positive T-cells (A) were stained for CD27, CD45RA and CD95 to further define T-cell subsets (B). To study T cell function, Boolean gating analysis was used. PBMC were stimulated with HKx31 (MOI10) (C) influenza virus peptide pool (D) PMA/I (E) and Dynabeads (F) for 18 hours. PBMC were then stained for CD107a, IFNγ, MIP-1β and TNF. Statistical significance was determined as described in the Materials and Methods. Bars and error bars represent means (±SEM). Gating was performed as previously described¹⁰. *: p<0.05.

329 DISCUSSION:

Individuals with diabetes can experience significant intra and inter-day fluctuations in blood glucose levels. To date, the effect of these fluctuations on the T-cell response to influenza virus, or other viral diseases, has been undefined. Here, we provide the show that this glycaemic variability is associated with changes in the T-cell population and reduced CD8⁺ T cell TNF production to *ex vivo* stimulation with influenza virus.

Patients with high glycaemic variability had a significantly higher percentage of T_{naive} CD8⁺ T-cells 335 compared to patients with low glycaemic variability. Considering the clinical evidence that high 336 glycaemic variability is associated with more severe viral disease^{4,9-13} it is interesting to speculate 337 what functional consequences increased T_{naive} CD8⁺ T-cell population may have. Whether this 338 339 represents a population of T-cells that is unable to differentiate into functional effector or memory 340 cells (which would then likely be associated with an impaired immune response) remains to be 341 determined. Therefore, the clinical consequences of these observations, if any, require further 342 investigation.

343 In the present study we observed a reduced proportion of CD8+CD107 α -IFNy-MIP1 β -TNF+ T-cells in 344 response to stimulation with influenza virus. This same phenomenon was not observed following 345 stimulation with non-specific stimuli (such as PMA/I or Dynabeads). This suggests that high 346 glycaemic variability does not impair CD8+T cell function per sae rather more specifically the 347 response to influenza virus or viral stimulation. The production of TNF by CD8+ T cells during a viral 348 infection is essential for the induction of apoptosis, the recruitment and activation of other immune 349 cells, CD8+ T-cell function and the regulation of anti-viral immunity. However, TNF produced by CD8+ T-cells during influenza virus infection can also cause 'bystander damage' of pulmonary 350 epithelial cells, resulting in immunopathology²¹. Therefore, whether these observations contribute 351 352 to the increased influenza severity in individuals with diabetes with high glycaemic variability^{4,9-13} 353 remains to be determined. Nevertheless, these data provide the evidence that assessing glycaemic 354 variability may provide an important insight into the anti-viral CD8+ T-cell response of individuals 355 living with diabetes.

356 The precise mechanism by which high glycaemic variability may reduce the TNF response of CD8 T-357 cells and affect the proportion of T_{naive} and T_{EMRA} CD8⁺ T-cells remains unclear. There is a growing 358 body of evidence that glycaemic variability is associated with increased oxidative stress and the production of radical oxygen species (ROS) relative to steady state hyperglycaemia ²². This may 359 directly affect T-cell function. For example, short pre-exposure of human PBMC to H₂O₂ reduces the 360 361 ability of activated/memory $CD3^+$ and $CD8^+$ T-cells (CD45RO⁺) to produce key effector cytokines such as IFNy and TNF²³. This effect may be more pronounced in activated/memory T-cells ²³. Similarly, 362 over production of ROS is known to drive naïve T-cell proliferation^{24,25}. Whether these changes in 363 circulating T-cell population were the result of oxidative stress or another biological system affected 364 365 by glucose fluctuations in the blood remain to be determined.

366 Our study has some limitations that are important to acknowledge. Firstly, in the participant cohort 367 the sample size was low and glycaemic variability was categorized based on two weeks of CGM data. 368 Whether additional effects would have been detected if a longer period of CGM data were available 369 remains to be determined. It is also important to note that the participants recruited to this study all 370 had T1D. This patient group was selected as CGMs are more common amongst those living with T1D. 371 Interestingly, recent evidence suggests that in patients with T2D who did wear CGMs glycaemic 372 variability was associated with changes in the T cell population (namely an altered Th1/Th2 ratio and 373 frequency of Tregs)²⁶. These data suggest that the differences observed in T cell populations

observed herein may not be restricted to patients with T1D²⁶. Finally, additional patient information

- such as GAD positivity or beta cell function was not recorded and may have influenced the results.
- 376

In sum, this study has provided evidence that glycaemic variability, rather than steady-state hyperglycaemia, effects T cell responses to influenza virus. These data have important implications for clinical practice. Specifically, these data suggest that glycaemic variability provides a possible predicative approach to assess anti-viral immunity, thus providing better management of infectious diseases in this patient population. Indeed, these data represent a further impetus to make CGMs widely available to patients with both T1D and T2D.

383

384

385

386

387

388 ACKNOWLEDGEMENTS

We would like to thank all individuals who participated in this study. This project was supported by the National Health and Medical Research Council (NHMRC; APP1159959). KRS is supported by NHMRC investigator grant 2007919. CES was supported by the ARC-DECRA Fellowship (#DE220100185) and the University of Melbourne Establishment Grant. KK was supported by the NHMRC Leadership Investigator Grant (#1173871). EJG is supported by an Australian Research Council (ARC) DECRA Fellowship (DE210101479). SG is supported by an NHMRC Senior Research Fellowship (#1159272). L.C.R. is a recipient of a NHMRC EL1 Fellowship (#2026357).

396

397 The authors declare no competing interest.

398

399

400

401

402

403

404

405 406

407

408

409

411 **REFERENCES**

412	1. Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or complicated influenza
413	illness: systematic review and meta-analysis. <i>Bmj</i> 2013; 347 .
414	2. Allard R, Leclerc P, Tremblay C, Tannenbaum T-N. Diabetes and the severity of pandemic
415	influenza A (H1N1) infection. <i>Diabetes care</i> 2010; 33 (7): 1491-3.
416	3. Longmore DK, Miller JE, Bekkering S, et al. Diabetes and overweight/obesity are
417	independent, nonadditive risk factors for in-hospital severity of COVID-19: an international,
418	multicenter retrospective meta-analysis. <i>Diabetes Care</i> 2021; 44 (6): 1281-90.
419	4. Zhu L, She Z-G, Cheng X, et al. Association of blood glucose control and outcomes in patients
420	with COVID-19 and pre-existing type 2 diabetes. Cell metabolism 2020; 31 (6): 1068-77. e3.
421	5. Chen Z, Liu Q, Song R, et al. The association of glycemic level and prevalence of tuberculosis:
422	a meta-analysis. <i>BMC Endo Dis</i> 2021; 21 (1): 123.
423	6. Charoenngam N, Alexanian SM, Apovian CM, Holick MF. Association between Hyperglycemia
424	at Hospital Presentation and Hospital Outcomes in COVID-19 Patients with and without Type 2
425	Diabetes: A Retrospective Cohort Study of Hospitalized Inner-City COVID-19 Patients. <i>Nutrients</i> 2021;
426	13 (7): 2199.
427	7. Hulme KD, Yan L, Marshall RJ, et al. High glucose levels increase influenza-associated damage
428	to the pulmonary epithelial-endothelial barrier. <i>eLife</i> 2020; 9 : e56907.
429	8. Hulme KD, Tong ZWM, Rowntree LC, et al. Increasing HbA1c is associated with reduced
430	CD8(+) T cell functionality in response to influenza virus in a TCR-dependent manner in individuals
431	with diabetes mellitus. <i>Cell Mol Life Sci</i> 2024; 81 (1): 35.
432	9. Marshall RJ, Armart P, Hulme KD, et al. Glycemic variability in diabetes increases the severity
433	of influenza. <i>MBio</i> 2020; 11 (2): 10.1128/mbio. 02841-19.
434	10. Hulme KD, Gallo LA, Short KR. Influenza virus and glycemic variability in diabetes: a killer
435	combination? Frontiers in microbiology 2017; 8 : 264999.
436	11. Hartmann B, Verket M, Balfanz P, et al. Glycaemic variability is associated with all-cause
437	mortality in COVID-19 patients with ARDS, a retrospective subcohort study. Scientific reports 2022;
438	12 (1): 9862.
439	12. Ali El Chab Parolin S, Benicio Stocco R, Kneipp Lopes JdC, et al. Association between inpatient
440	glycemic variability and COVID-19 mortality: a prospective study. <i>Diabetology & Metabolic Syndrome</i>
441	2023; 15 (1): 185.
442	13. Hoong CWS, Yeo XE, Lin Y, Ooi ST, Yeoh E. High glycaemic variability is associated with
443	progression of COVID-19. Acta Diabetologica 2021; 58 (12): 1701-4.
444	14. Piona C, Marigliano M, Mozzillo E, et al. Relationships between HbA1c and continuous
445	glucose monitoring metrics of glycaemic control and glucose variability in a large cohort of children
446	and adolescents with type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> 2021; 177 : 108933.
447	15. Rama Chandran S, Tay WL, Lye WK, et al. Beyond HbA1c: Comparing Glycemic Variability and
448	Glycemic Indices in Predicting Hypoglycemia in Type 1 and Type 2 Diabetes. Diabetes Technology &
449	Therapeutics 2018; 20 (5): 353-62.
450	16. Van Dalem A, Demeester S, Balti EV, et al. Relationship between glycaemic variability and
451	hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes. Diabetologia
452	2015; 58 : 2753-64.
453	17. Short KR, Diavatopoulos DA, Reading PC, et al. Using bioluminescent imaging to investigate
454	synergism between Streptococcus pneumoniae and influenza A virus in infant mice. J Vis Exp 2011;
455	(50): 2357.
456	18. Hulme KD, Tong ZWM, Rowntree LC, et al. Increasing HbA1c is associated with reduced CD8+
457	T cell functionality in response to influenza virus in a TCR-dependent manner in individuals with
458	diabetes mellitus. Cellular and Molecular Life Sciences 2024; 81(1): 35.
459	19. Martinez M, Santamarina J, Pavesi A, Musso C, Umpierrez GE. Glycemic variability and
460	cardiovascular disease in patients with type 2 diabetes. 2021; 9 (1): e002032.

461 20. Hensen L, Illing P, Clemens EB, et al. CD8+ T cell landscape in Indigenous and non-Indigenous 462 people restricted by influenza mortality-associated HLA-A*24:02 allomorph. 2021.

463 21. Van De Sandt CE, Bárcena M, Koster AJ, et al. Human CD8+ T cells damage noninfected 464 epithelial cells during influenza virus infection in vitro. *American Journal of Respiratory Cell and*

465 Molecular Biology 2017; 57(5): 536-46.
466 22. Papachristoforou E, Lambadiari V, Maratou E, Makrilakis K. Association of Glycemic Indices

(Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic
Complications. J Diabetes Res 2020; 2020: 7489795.

469 23. Malmberg KJ, Arulampalam V, Ichihara F, et al. Inhibition of activated/memory (CD45RO(+))

T cells by oxidative stress associated with block of NF-kappaB activation. *Journal of immunology*(*Baltimore, Md : 1950*) 2001; **167**(5): 2595-601.

472 24. Yarosz EL, Chang C-H. The Role of Reactive Oxygen Species in Regulating T Cell-mediated 473 Immunity and Disease. *Immune Netw* 2018; **18**(1).

474 25. Rashida Gnanaprakasam JN, Wu R, Wang R. Metabolic Reprogramming in Modulating T Cell 475 Reactive Oxygen Species Generation and Antioxidant Capacity. *Front Immunol* 2018; **9**: 1075.

476 26. Sun Q, Yang P, Gu Q-W, et al. Increased glycemic variability results in abnormal

477 differentiation of T cell subpopulation in type 2 diabetes patients. *Journal of Diabetes and its*

478 *Complications* 2024; **38**(6): 108738.